gabexate has been researched along with Cystic Fibrosis in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF)." | 9.17 | Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis. ( Abbi, S; Clancy, JP; Danahay, H; Hathorne, H; Lock, R; Reeves, G; Renard, D; Rowe, SM; Solomon, GM; Waltz, DA; Zhou, P, 2013) |
| " Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF)." | 5.17 | Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis. ( Abbi, S; Clancy, JP; Danahay, H; Hathorne, H; Lock, R; Reeves, G; Renard, D; Rowe, SM; Solomon, GM; Waltz, DA; Zhou, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rowe, SM | 1 |
| Reeves, G | 1 |
| Hathorne, H | 1 |
| Solomon, GM | 1 |
| Abbi, S | 1 |
| Renard, D | 1 |
| Lock, R | 1 |
| Zhou, P | 1 |
| Danahay, H | 1 |
| Clancy, JP | 1 |
| Waltz, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients[NCT04530617] | Phase 2 | 246 participants (Actual) | Interventional | 2020-10-05 | Terminated (stopped due to Results from the interim analysis) | ||
| A Two-part, Randomized, Double-blind, Placebo-controlled, Ascending Single-dose, Adaptive Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAU145 Administered Via a Nasal Spray Pump to Patients With Cystic Fibrosis[NCT00506792] | Phase 2 | 9 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for gabexate and Cystic Fibrosis
| Article | Year |
|---|---|
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
Topics: Administration, Intranasal; Adult; Biological Transport; Chlorides; Cross-Over Studies; Cystic Fibro | 2013 |
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
Topics: Administration, Intranasal; Adult; Biological Transport; Chlorides; Cross-Over Studies; Cystic Fibro | 2013 |
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
Topics: Administration, Intranasal; Adult; Biological Transport; Chlorides; Cross-Over Studies; Cystic Fibro | 2013 |
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
Topics: Administration, Intranasal; Adult; Biological Transport; Chlorides; Cross-Over Studies; Cystic Fibro | 2013 |